Twiner Michael J, Marinica Alexander L, Kuper Kenneth, Goodman Allen, Mahn James J, Burla Michael J, Brody Aaron M, Carroll Justin A, Josiah Willock Robina, Flack John M, Nasser Samar A, Levy Phillip D
Department of Emergency Medicine, Wayne State University, Detroit, MI.
Department Surgery, Sinai Grace Hospital, Detroit, MI.
Acad Emerg Med. 2017 Feb;24(2):168-176. doi: 10.1111/acem.13122. Epub 2017 Jan 30.
Poorly controlled hypertension (HTN) is extremely prevalent and, if left unchecked, subclinical hypertensive heart disease (SHHD) may ensue leading to conditions such as heart failure. To address this, we designed a multidisciplinary program to detect and treat SHHD in a high-risk, predominantly African American community. The primary objective of this study was to determine the cost-effectiveness of our program.
Study costs associated with identifying and treating patients with SHHD were calculated and a sensitivity analysis was performed comparing the effect of four parameters on cost estimates. These included prevalence of disease, effectiveness of treatment (regression of SHHD, reversal of left ventricular hypertrophy [LVH], or blood pressure [BP] control as separate measures), echocardiogram costs, and participant time/travel costs. The parent study for this analysis was a single-center, randomized controlled trial comparing cardiac effects of standard and intense (<120/80 mm Hg) BP goals at 1 year in patients with uncontrolled HTN and SHHD. A total of 149 patients (94% African American) were enrolled, 133 (89%) had SHHD, 123 (93%) of whom were randomized, with 88 (72%) completing the study. Patients were clinically evaluated and medically managed over the course of 1 year with repeated echocardiograms. Costs of these interventions were analyzed and, following standard practices, a cost per quality-adjusted life-year (QALY) less than $50,000 was defined as cost-effective.
Total costs estimates for the program ranged from $117,044 to $119,319. Cost per QALY was dependent on SHHD prevalence and the measure of effectiveness but not input costs. Cost-effectiveness (cost per QALY less than $50,000) was achieved when SHHD prevalence exceeded 11.1% for regression of SHHD, 4.7% for reversal of LVH, and 2.9% for achievement of BP control.
In this cohort of predominantly African American patients with uncontrolled HTN, SHHD prevalence was high and screening with treatment was cost-effective across a range of assumptions. These data suggest that multidisciplinary programs such as this can be a cost-effective mechanism to mitigate the cardiovascular consequences of HTN in emergency department patients with uncontrolled BP.
控制不佳的高血压(HTN)极为普遍,若不加以控制,可能会引发亚临床高血压性心脏病(SHHD),进而导致心力衰竭等病症。为解决这一问题,我们设计了一个多学科项目,用于在一个高危、主要为非裔美国人的社区中检测和治疗SHHD。本研究的主要目的是确定我们项目的成本效益。
计算了识别和治疗SHHD患者的研究成本,并进行了敏感性分析,比较了四个参数对成本估算的影响。这些参数包括疾病患病率、治疗效果(SHHD的消退、左心室肥厚[LVH]的逆转或血压[BP]控制作为单独指标)、超声心动图成本以及参与者的时间/交通成本。该分析的母研究是一项单中心随机对照试验,比较了标准血压目标和强化血压目标(<120/80 mmHg)对未控制的HTN和SHHD患者1年内心脏影响。共招募了149名患者(94%为非裔美国人),其中133名(89%)患有SHHD,123名(93%)被随机分组,88名(72%)完成了研究。在1年的时间里,对患者进行了临床评估和医学管理,并多次进行超声心动图检查。分析了这些干预措施的成本,按照标准做法,每质量调整生命年(QALY)成本低于50,000美元被定义为具有成本效益。
该项目的总成本估算范围为117,044美元至119,319美元。每QALY成本取决于SHHD患病率和效果指标,但不取决于投入成本。当SHHD患病率超过11.1%时,SHHD消退可实现成本效益(每QALY成本低于50,000美元);当LVH逆转的患病率超过4.7%时,可实现成本效益;当实现血压控制的患病率超过2.9%时,可实现成本效益。
在这个主要为未控制HTN的非裔美国患者队列中,SHHD患病率很高,在一系列假设条件下,筛查并治疗具有成本效益。这些数据表明,这样的多学科项目可以成为一种具有成本效益的机制,以减轻急诊科血压未控制患者HTN的心血管后果。